Switch to:
Also traded in: Germany, South Africa

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.21
OTCPK:APNHF's Cash-to-Debt is ranked lower than
86% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. OTCPK:APNHF: 0.21 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:APNHF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 0.35 Max: N/A
Current: 0.21
Equity-to-Asset 0.37
OTCPK:APNHF's Equity-to-Asset is ranked lower than
80% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. OTCPK:APNHF: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:APNHF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.45 Max: 0.55
Current: 0.37
0.31
0.55
Interest Coverage 3.77
OTCPK:APNHF's Interest Coverage is ranked lower than
85% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.29 vs. OTCPK:APNHF: 3.77 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:APNHF' s Interest Coverage Range Over the Past 10 Years
Min: 3.11  Med: 4.82 Max: 5.91
Current: 3.77
3.11
5.91
Piotroski F-Score: 5
Altman Z-Score: 2.37
Beneish M-Score: -2.45
WACC vs ROIC
9.92%
7.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 19.79
OTCPK:APNHF's Operating Margin % is ranked higher than
81% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. OTCPK:APNHF: 19.79 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:APNHF' s Operating Margin % Range Over the Past 10 Years
Min: 19.79  Med: 25.66 Max: 26.74
Current: 19.79
19.79
26.74
Net Margin % 9.76
OTCPK:APNHF's Net Margin % is ranked higher than
65% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. OTCPK:APNHF: 9.76 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:APNHF' s Net Margin % Range Over the Past 10 Years
Min: 9.76  Med: 18.03 Max: 20.82
Current: 9.76
9.76
20.82
ROE % 8.86
OTCPK:APNHF's ROE % is ranked higher than
58% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. OTCPK:APNHF: 8.86 )
Ranked among companies with meaningful ROE % only.
OTCPK:APNHF' s ROE % Range Over the Past 10 Years
Min: 8.86  Med: 20.48 Max: 38.57
Current: 8.86
8.86
38.57
ROA % 3.49
OTCPK:APNHF's ROA % is ranked higher than
50% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. OTCPK:APNHF: 3.49 )
Ranked among companies with meaningful ROA % only.
OTCPK:APNHF' s ROA % Range Over the Past 10 Years
Min: 3.49  Med: 9.51 Max: 12.24
Current: 3.49
3.49
12.24
ROC (Joel Greenblatt) % 29.17
OTCPK:APNHF's ROC (Joel Greenblatt) % is ranked higher than
72% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. OTCPK:APNHF: 29.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:APNHF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 29.17  Med: 63.55 Max: 146.66
Current: 29.17
29.17
146.66
3-Year Revenue Growth Rate 22.60
OTCPK:APNHF's 3-Year Revenue Growth Rate is ranked higher than
85% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. OTCPK:APNHF: 22.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:APNHF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 15  Med: 23.3 Max: 33.4
Current: 22.6
15
33.4
3-Year EBITDA Growth Rate 22.60
OTCPK:APNHF's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. OTCPK:APNHF: 22.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:APNHF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 24.1 Max: 46.5
Current: 22.6
0
46.5
3-Year EPS without NRI Growth Rate 7.00
OTCPK:APNHF's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. OTCPK:APNHF: 7.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:APNHF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 7  Med: 26.6 Max: 365.5
Current: 7
7
365.5
GuruFocus has detected 6 Warning Signs with Aspen Pharmacare Holdings Ltd $OTCPK:APNHF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:APNHF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with APNHF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:NYSE:PRGO, OTCPK:HLUKF, OTCPK:SFOSF, OTCPK:MTZPY, OTCPK:IPSEY, OTCPK:GNHAF, NYSE:RDY, NYSE:VRX, OTCPK:HYPMY, OTCPK:MKGAY, OTCPK:SGIOY, NYSE:TARO, NYSE:MNK, NAS:OPK, OTCPK:ESALF, NYSE:PTHN, NAS:NBIX, NAS:MDCO, OTCPK:STDAF, NYSE:CTLT » details
Traded in other countries:LDZA.Germany, APN.South Africa,
Aspen Pharmacare Holdings Ltd through its subsidiaries, is engaged in manufacturing, marketing and distribution of branded and generic pharmaceutical, as well as nutritional products.

Aspen Pharmacare Holdings Ltd is a pharmaceutical company. The Company, through its subsidiaries, is engaged in the manufacture, marketing and distribution of branded and generic pharmaceutical, as well as consumer, OTC and nutritional products in selected territories, operating primarily in the healthcare industry. Its product types includes tablets, capsules, eye drops, injectable products (including lyophilized vials), oral contraceptives, form-filled seals, suppositories, liquids, creams, ointments, infant nutritional products, and specialist active pharmaceutical ingredients. The Company operates in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, France, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States of America.

Ratios

vs
industry
vs
history
PE Ratio 32.66
APNHF's PE Ratio is ranked lower than
60% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.50 vs. APNHF: 32.66 )
Ranked among companies with meaningful PE Ratio only.
APNHF' s PE Ratio Range Over the Past 10 Years
Min: 12.7  Med: 20.62 Max: 40.2
Current: 32.66
12.7
40.2
PE Ratio without NRI 32.66
APNHF's PE Ratio without NRI is ranked lower than
60% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.49 vs. APNHF: 32.66 )
Ranked among companies with meaningful PE Ratio without NRI only.
APNHF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.99  Med: 22.09 Max: 40.2
Current: 32.66
12.99
40.2
PB Ratio 3.15
APNHF's PB Ratio is ranked lower than
53% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.93 vs. APNHF: 3.15 )
Ranked among companies with meaningful PB Ratio only.
APNHF' s PB Ratio Range Over the Past 10 Years
Min: 2.66  Med: 4.39 Max: 8.41
Current: 3.15
2.66
8.41
PS Ratio 3.50
APNHF's PS Ratio is ranked lower than
56% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. APNHF: 3.50 )
Ranked among companies with meaningful PS Ratio only.
APNHF' s PS Ratio Range Over the Past 10 Years
Min: 2.27  Med: 3.82 Max: 6.78
Current: 3.5
2.27
6.78
Price-to-Free-Cash-Flow 312.02
APNHF's Price-to-Free-Cash-Flow is ranked lower than
94% of the 228 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.42 vs. APNHF: 312.02 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
APNHF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 22.73  Med: 90.64 Max: 433.79
Current: 312.02
22.73
433.79
Price-to-Operating-Cash-Flow 38.99
APNHF's Price-to-Operating-Cash-Flow is ranked lower than
78% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.18 vs. APNHF: 38.99 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
APNHF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.81  Med: 24.99 Max: 54.21
Current: 38.99
14.81
54.21
EV-to-EBIT 22.89
APNHF's EV-to-EBIT is ranked lower than
58% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. APNHF: 22.89 )
Ranked among companies with meaningful EV-to-EBIT only.
APNHF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 15.5 Max: 29.6
Current: 22.89
6.8
29.6
EV-to-EBITDA 22.89
APNHF's EV-to-EBITDA is ranked lower than
68% of the 573 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.30 vs. APNHF: 22.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
APNHF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 14.9 Max: 28.1
Current: 22.89
6.8
28.1
PEG Ratio 1.04
APNHF's PEG Ratio is ranked higher than
70% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.79 vs. APNHF: 1.04 )
Ranked among companies with meaningful PEG Ratio only.
APNHF' s PEG Ratio Range Over the Past 10 Years
Min: 0.39  Med: 1.27 Max: 3.99
Current: 1.04
0.39
3.99
Shiller PE Ratio 40.81
APNHF's Shiller PE Ratio is ranked higher than
57% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.64 vs. APNHF: 40.81 )
Ranked among companies with meaningful Shiller PE Ratio only.
APNHF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 39.99  Med: 60.87 Max: 90.84
Current: 40.81
39.99
90.84
Current Ratio 1.48
APNHF's Current Ratio is ranked lower than
74% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. APNHF: 1.48 )
Ranked among companies with meaningful Current Ratio only.
APNHF' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.4 Max: 1.95
Current: 1.48
0.7
1.95
Quick Ratio 0.94
APNHF's Quick Ratio is ranked lower than
78% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. APNHF: 0.94 )
Ranked among companies with meaningful Quick Ratio only.
APNHF' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 0.97 Max: 1.31
Current: 0.94
0.49
1.31
Days Inventory 257.63
APNHF's Days Inventory is ranked lower than
90% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. APNHF: 257.63 )
Ranked among companies with meaningful Days Inventory only.
APNHF' s Days Inventory Range Over the Past 10 Years
Min: 115.22  Med: 143.67 Max: 259.83
Current: 257.63
115.22
259.83

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate 11.20
APNHF's 3-Year Dividend Growth Rate is ranked higher than
55% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.10 vs. APNHF: 11.20 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
APNHF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.2 Max: 63.4
Current: 11.2
0
63.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.53
APNHF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. APNHF: 2.53 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
APNHF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 3.82 Max: 5.84
Current: 2.53
0
5.84
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.15
APNHF's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
57% of the 63 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.28 vs. APNHF: 1.15 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.92
APNHF's Price-to-Median-PS-Value is ranked lower than
99.99% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. APNHF: 0.92 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
APNHF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.89 Max: 1.41
Current: 0.92
0
1.41
Price-to-Peter-Lynch-Fair-Value 1.16
APNHF's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. APNHF: 1.16 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
APNHF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 0.99 Max: 1.81
Current: 1.16
0
1.81
Earnings Yield (Greenblatt) % 4.37
APNHF's Earnings Yield (Greenblatt) % is ranked higher than
62% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. APNHF: 4.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
APNHF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 6.45 Max: 14.8
Current: 4.37
3.4
14.8
Forward Rate of Return (Yacktman) % 28.51
APNHF's Forward Rate of Return (Yacktman) % is ranked higher than
82% of the 364 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.76 vs. APNHF: 28.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
APNHF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.6  Med: 20.6 Max: 35.5
Current: 28.51
1.6
35.5

More Statistics

Revenue (TTM) (Mil) $2,634
EPS (TTM) $ 0.59
Beta1.65
Short Percentage of Float0.00%
52-Week Range $18.76 - 72.66
Shares Outstanding (Mil)456.00
» More Articles for APNHF

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Gains 5 New Stocks Feb 01 2017 

More From Other Websites
Aspen Pharmacare Holdings Ltd. :APNHF-US: Earnings Analysis: For the six months ended December 31,... Mar 14 2017
Aspen Pharmacare Holdings Ltd. : Neutral price; Buy/ Sell depends on fundamentals Mar 02 2017
Europe faces steep price increases for some old cancer drugs Jan 28 2017
Aspen Pharmacare Holdings Ltd. breached its 50 day moving average in a Bullish Manner : APNHF-US :... Jan 12 2017
Aspen Pharmacare Holdings Ltd. breached its 50 day moving average in a Bullish Manner : APNHF-US :... Dec 30 2016
Aspen Pharmacare Holdings Ltd. : At a good price point right now? Dec 20 2016
Glaxo Sells Stake in South Africa’s Aspen for $619 Million Sep 28 2016
South Africa's Aspen Pharmacare FY profit drops 23 percent Sep 14 2016
Aspen Pharmacare moves into China as South Africa sales dip Sep 14 2016
Aspen Targets Further Chinese Acquisitions After Glaxo Deal Sep 14 2016
GSK sells anaesthetics to Aspen for up to $370 million Sep 12 2016
GSK sells anaesthetics to Aspen for up to $370 million Sep 12 2016
GSK sells anaesthetics to Aspen for up to $370 million Sep 12 2016
GSK sells anaesthetics to Aspen for up to $370 mln Sep 12 2016
Aspen Tumbles Most in Two Years on Venezuela Loss, Disposals Sep 07 2016
Aspen Expands in China as African Drugmaker Targets Growth Jul 19 2016
AstraZeneca sells rights to anesthetics for up to $770 million Jun 09 2016
AstraZeneca sells rights to anaesthetics for up to $770 mln Jun 09 2016
Aspen to Buy Anesthetics From AstraZeneca for $520 Million Jun 09 2016
AstraZeneca sells rights to anaesthetics to South Africa's Aspen Jun 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)